WCN25-1188 THE USEFULNESS OF URINARY N-ACETYL- β-D-GLUCOSAMINIDASE-CREATININE RATIO AS THE BIOMARKER TO DECIDE LONG-TERM USE OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITOR IN DIABETIC KIDNEY DISEASE

Diabetic kidney disease (DKD) is rapidly increasing worldwide. Albuminuria and serum creatinine are clinically used as biomarkers indicating the progression of DKD. Unfortunately, these biomarkers cannot reflect early renal damage in chronic kidney disease including DKD. The N-acetyl-β-D-glucosaminidase (NAG) is found in the lysosomes of renal proximal tubular cells and the urinary NAG can reflect even subclinical tubular damage. Recently, the use of sodium-glucose cotransporter 2 inhibitor (SGLT2i) is prominently increased in diabetic kidney disease.